ArticleMedical & biological engineering & computing2022
Sparse principal component analysis based on genome network for correcting cell type heterogeneity in epigenome-wide association studies.
Article in Medical & biological engineering & computing, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
In epigenome-wide association studies (EWAS), the mixed methylation expression caused by the combination of different cell types may lead the researchers to find the false methylation site related to the phenotype of interest. To correct the EWAS false discovery, some non-reference models based on sparse principal component analysis (sparse PCA) have been proposed. These models assume that all methylation sites have the same priori probability in each PC load. However, it is known that there already has gene network structure corresponding to the methylation site. How to integrate this genome network knowledge into the sparse PCA models to enhance the performance of existing models is an open research problem. We introduce GN-ReFAEWAS, a non-reference analysis model which integrates the prior gene network structure into the PCA framework to control the false discovery in EWAS. We used one simulated data set, three real data sets, and three additional tests for experiments and compared with four existing models. Experimental results show that the GN-ReFAEWAS model is better than the existing model by 2-90% in the indicators of sensitivity, specificity, genomic control factor λ, and correlation coefficient factor cov with known cell phenotype ratio.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.